SCHEMBL16178553

SCHEMBL16178553

COc1cccc2sc(NC(=O)N3CCNCC3)nc12

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 1/20 0.63
▸ NPY5R Q15761 1/20 0.58
▸ DUSP3 P51452 2/20 0.56
▸ CHRM4 P08173 1/20 0.56
▸ MEN1 O00255 6/20 0.54
▸ KMT2A Q03164 6/20 0.54
▸ KDM4E B2RXH2 3/20 0.54
▸ ALDH1A1 P00352 3/20 0.54
▸ HPGD P15428 3/20 0.54
▸ ADORA1 P30542 3/20 0.54
▸ NPC1 O15118 2/20 0.54
▸ RAB9A P51151 2/20 0.54
▸ TMIGD3 P0DMS9 1/20 0.54
▸ PPARG P37231 1/20 0.54
▸ NPSR1 Q6W5P4 1/20 0.54
▸ NR2E3 Q9Y5X4 1/20 0.54
▸ NCOR2 Q9Y618 1/20 0.54
▸ ACP1 P24666 1/20 0.53
▸ MAPT P10636 7/20 0.52
▸ GAA P10253 4/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5464554 0.88 DYRK1A (0.65) DYRK1ANPY5RDUSP3CHRM4MEN1
SCHEMBL30961688 0.81 CHRM4 (0.56) DYRK1ADUSP3CHRM4MEN1KMT2A
SCHEMBL27192341 0.81 CHRM4 (0.56) DYRK1ADUSP3CHRM4MEN1KMT2A
SCHEMBL29471912 0.78 TMIGD3 (0.53) DYRK1ADUSP3CHRM4MEN1KMT2A
SCHEMBL27192236 0.78 TMIGD3 (0.56) DYRK1ADUSP3CHRM4MEN1KMT2A
SCHEMBL30961690 0.78 TMIGD3 (0.56) DYRK1ADUSP3CHRM4MEN1KMT2A
SCHEMBL27192387 0.78 TMIGD3 (0.53) DYRK1ADUSP3CHRM4MEN1KMT2A
SCHEMBL15376502 0.78 DYRK1A (1.00) DYRK1ADUSP3CHRM4MEN1KMT2A
SCHEMBL20660046 0.78 DYRK1A (0.80) DYRK1ADUSP3CHRM4MEN1KMT2A
SCHEMBL3047328 0.78 DYRK1A (0.80) DYRK1ADUSP3CHRM4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096614-B2 Therapeutically active thiazolo-pyrimidine derivatives UCB PHARMA SA (BE) 2015-08-04 — — US disclosed
US-20140315885-A1 Therapeutically Active Thiazolo-Pyrimidine Derivatives UCB PHARMA SA (BE) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315885-A1 Therapeutically Active Thiazolo-Pyrimidine Derivatives TPMT, IFNG, IRF3 DYRK1A 1917/4885NPY5R 1677/4885DUSP3 252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback